Clinical Trials · NCT03087032
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
- Phase
- Phase 4
- Recruitment status
- Recruiting
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Enrollment
- 164
- Start date
- Jan 2019
- Locations
- 1 site, China
- Primary endpoint
- the proportion of patients with HbA1c < 7.0% without experiencing hypoglycemia and without weight gain,with a superiority margin of 3%